Mode
Text Size
Log in / Sign up
N/A N=37 Randomized Double-blind Treatment

Fish Oil for HIV-Related Inflamm-aging and Immune Senescence

HIV Infection

Enrolled (actual)
37
Serious AEs
5.4%
Results posted
Mar 2019
Primary outcome: Primary: Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation — 1.87; 4.22; -2.83; -1.56 percentage of cells — p=< 0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Fish oil that contains omega-3 fatty acids (Dietary_supplement); Placebo (Dietary_supplement)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
Rush University Medical Center
Primary completion
Dec 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation
1.87; 4.22; -2.83; -1.56; 0.69; -2.41 < 0.05 sig

Summary

HIV infection is associated with premature aging of the immune system. It is believe that the persistent inflammation that accompanies HIV infection is a major contributor to premature immune aging. Fish oil has well-documented anti-inflammatory properties. In this randomized, clinical trial, we're testing whether a 12-week course of fish oil supplementation will reverse premature aging in HIV-infected older adults.

Eligibility Criteria

Inclusion Criteria

  • documented HIV infection
  • between 40 and 70 years of age
  • clinically stable HIV disease as evidenced by a CD4+ T lymphocyte count of > 250 cells/mm3
  • platelet count between 150, 000 and 400,000 cells/mm3 to reduce bleeding risks associated with omega 3-fatty acids
  • treatment with a stable HAART regimen for at least six months prior to study entry
  • plasma HIV RNA 2.0 mg/L).

Exclusion Criteria

  • use within the past month of drugs (e.g., statins, steroids, hormones) and supplements (e.g., omega-3 fatty acids, glucosamine/chondroitin) that have anti-inflammatory effects (excluding non-regular use of aspirin or NSAIDS), or medications or supplements that affect bleeding (e.g., heparin, warfarin, clopidogrel, garlic, ginseng)
  • allergy to fish or shellfish
  • chronic inflammatory condition (e.g., asthma, rheumatoid arthritis), opportunistic infection or cancer, renal impairment (serum creatinine > 2.0 mg/dL), thrombocytopenia (platelet count 35, since obesity is associated with inflammation
  • impaired liver function as evidenced by liver enzyme elevations > three times the upper limit of normal (AST or ALT > 150 IU/L)
  • history of prostate cancer
  • LDL cholesterol level > 120 mg/dL
  • lifestyle exclusion factors include use of illicit drugs and consumption of > 3 alcoholic drinks/day
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02102724). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search